GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 1,430 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,430 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20. Following the completion of the sale, the chief financial officer now owns 26,770 shares of the company’s stock, valued at approximately $2,035,590.80. This trade represents a 5.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total transaction of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total value of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total value of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $18,248.40.

GeneDx Trading Down 0.5 %

Shares of GeneDx stock opened at $96.57 on Thursday. The company has a 50-day moving average of $77.48 and a two-hundred day moving average of $52.46. The stock has a market cap of $2.65 billion, a PE ratio of -31.05 and a beta of 2.02. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 12-month low of $2.85 and a 12-month high of $98.87.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The company had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. During the same period in the previous year, the business earned ($0.82) earnings per share. GeneDx’s quarterly revenue was up 44.3% compared to the same quarter last year. On average, research analysts anticipate that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On GeneDx

Several hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new stake in shares of GeneDx in the second quarter valued at about $34,000. CWM LLC acquired a new stake in GeneDx during the 3rd quarter valued at $89,000. SG Americas Securities LLC purchased a new position in GeneDx during the third quarter worth $198,000. Point72 DIFC Ltd acquired a new position in shares of GeneDx in the third quarter worth $220,000. Finally, Palumbo Wealth Management LLC acquired a new position in shares of GeneDx in the third quarter worth $287,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Craig Hallum upped their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. TD Cowen increased their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday. The Goldman Sachs Group lifted their price objective on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company increased their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $70.67.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.